Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2022 Oct 27.
Published in final edited form as: J Phys Chem B. 2022 Aug 1;126(31):5832–5841. doi: 10.1021/acs.jpcb.2c04797

Nanoscale Infrared Spectroscopy Identifies Structural Heterogeneity in Individual Amyloid Fibrils and Prefibrillar Aggregates

Siddhartha Banerjee 1, Brooke Holcombe 1, Sydney Ringold 1, Abigail Foes 1, Tanmayee Naik 1, Divya Baghel 1, Ayanjeet Ghosh 1,*
PMCID: PMC9612939  NIHMSID: NIHMS1840087  PMID: 35914320

Abstract

Amyloid plaques are one of the central manifestations of Alzheimer’s disease pathology. Aggregation of the amyloid beta (Aβ) protein from amorphous oligomeric species to mature fibrils has been extensively studied. However, structural heterogeneities in prefibrillar species, and how that affects the structure of later stage aggregates are not yet well understood. The integration of infrared spectroscopy with Atomic Force Microscopy (AFM-IR) allows for identifying the signatures of individual nanoscale aggregates by spatially resolving spectra. We use AFM-IR to demonstrate that amyloid oligomers exhibit significant structural variations as evidenced in their infrared spectra. This heterogeneity is transmitted to and retained in protofibrils and fibrils. We show that amyloid fibrils do not always conform to their putative ordered structure and structurally different domains exist in the same fibril. We further demonstrate that these structural heterogeneities manifest themselves as lack of beta sheet structure in amyloid plaques in Alzheimer’s tissue using infrared imaging.

Keywords: Beta sheet, amyloid beta, AFM-IR, infrared, Alzheimer’s disease, heterogeneity

Graphical Abstract

graphic file with name nihms-1840087-f0001.jpg

Introduction

Aggregation of the amyloid beta (Aβ) protein into insoluble fibrillar deposits or plaques is a pathological hallmark of Alzheimer’s disease (AD)1. The mere presence of amyloid plaques, however, does not show correlation with cognitive decline25, and recent years have seen a paradigm shift in the pathological implications of Aβ plaques. It is now believed that soluble Aβ oligomers and prefibrillar aggregates and not mature fibrils are the primary neurotoxic species in AD69. The secondary structure of Aβ in fibrils and prefibrillar aggerates has also been studied extensively1014, and it is known that mature Aβ fibrils have a parallel beta sheet secondary structure1519, but Aβ oligomers may have antiparallel beta sheet structure20, 21. Although these studies provide valuable information, isolation and structural analysis of the amyloid aggregates formed at different stages of the aggregation still remains a challenge. The variations in protein structure within one subgroup of aggregates corresponding to a specific time point of aggregation are yet to be well understood. This is particularly relevant for early-stage aggregates such as oligomers and protofibrils. It is well-known that mature amyloid fibrils exhibit polymorphism: fibrils can have different morphologies which not only correspond to differences in molecular structure18, 22, 23, but are also associated with different stages of AD progression17, 24. However, little is known about structural polymorphism of early-stage aggregates. Essentially, it is not known if a particular type of aggregate can exhibit different secondary structures and if/how such structural heterogeneity can influence later stage aggregates. This gap in knowledge stems in part from the lack of suitable techniques that offer structural sensitivity and simultaneously are capable of spatially resolving specific aggregate species. Conventional approaches for protein structure determination, such as Nuclear Magnetic Resonance (NMR) and infrared spectroscopies do not offer spatial resolution and provide average spectra. As a result, it is not possible to assign spectral and hence structural attributes to specific aggregates, and it has to be assumed that all aggregates at a given stage of aggregation have the same average structure. The development of cryo-Electron Microscopy (cryo EM) has been able to address this limitation by spatially resolving structural variations in amyloid fibrils and promises to be an invaluable tool towards understanding amyloid structure2528. However, the applications of cryo-EM have been limited largely to mature fibrils, and hence there is need for experimental approaches that can isolate the structural facets of prefibrillar and early-stage aggregates. Integration of infrared spectroscopy with Atomic Force Spectroscopy (AFM) presents a perfect solution to this challenge.

AFM is a technique routinely used to study amyloid aggregates, and AFM-IR expands its capabilities by allowing for measurement of nanoscale infrared spectra of individual aggregates by utilizing the photothermal effect, where the local thermal expansion resulting from infrared absorption by a sample is sensed by an AFM tip2934 (Figure 1). AFM-IR thus combines the structural sensitivity of infrared spectroscopy with the nanoscale spatial resolution of AFM and allows for the identification of structural heterogeneity of aggregates by acquiring spectra of each member of the ensemble. In this study, we use AFM- IR to probe the structural distribution of Aβ42 oligomers and early-stage fibrils. Our findings show for the very first time that Aβ oligomers can exhibit a range of secondary structures and the integration of these heterogeneous oligomers into fibrils leads to fibrillar structural disorder, wherein different regions of the same fibril exhibit different structure, demonstrating that amyloid fibrils can deviate significantly from their putative structural uniformity.

Figure 1. Schematic description of AFM-IR.

Figure 1.

The AFM-IR measurement involves resonant excitation of the sample with infrared radiation, which leads to thermal expansion. The amplitude AFM cantilever oscillations resulting from this expansion are proportional to the infrared absorbance and lead to spatially localized nanoscale infrared spectra.

Materials and methods

Preparation of Aβ42 aggregates

Aβ42 (rPeptide, USA) was treated with 1,1,1,3,3,3-hexafluoroisopropanol (HFIP) to remove any preformed aggregates. HFIP was evaporated under vacuum and the stock solution was prepared in 1X PBS buffer (Sigma-Aldrich, USA) at pH 7.4. The concentration of Aβ42 was measured by UV spectrophotometer (Nanodrop, Thermo Scientific, USA), using an extinction coefficient of 1490 M−1cm−1 at 280 nm, since Aβ42 has single tyrosine residue35. The aggregation was carried out with 60 μM of Aβ42 in 1X PBS buffer at 37°C without any agitation.

Preparation of samples for AFM-IR experiment

Samples for AFM-IR experiments were prepared on ultraflat gold surface (Platypus Technologies, USA). 5 μl of the aggregation mixture was deposited at the center of the gold surface and incubated in a covered petri dish for 5 min. The substrate was subsequently gently rinsed with 500 μl milli-q water and dried under a stream of nitrogen gas.

AFM-IR experiment

AFM-IR experiments were performed with Bruker NanoIR3 equipment having mid-IR Quantum Cascade Laser (MIRcat, Daylight solutions). All AFM experiments were carried out in room temperature in tapping mode. The instrument was continuously purged with dry air to keep the relative humidity of less than 5% during the data collection. The cantilever resonance frequency has been 75 ±15 kHz and the spring constant is 1–7 N/m. Scan speeds were varied from 0.5–1.0 Hz. First a high-resolution AFM image of the sample were captured and then IR spectra has been recorded at different regions of interest. Spectra were recorded with 2 cm−1 resolution. 128 co-additions for each spectral point and 16 co-averages were applied for each spectrum.

Tissue imaging with infrared microscopy

Formalin fixed paraffin embedded (FFPE) human temporal lobe diseased tissue was purchased from Biochain Institute. The postmortem tissue specimens studied in this work are deidentified and were determined to be not human subjects research by the Office of Research Compliance at the University of Alabama. These tissues were deparaffinized in hexane for 24 prior to imaging. The microscope design is based upon work published by Bhargava and coworkers36, and has been described in detail elsewhere36, 37. The microscope uses a tunable Quantum Cascade Laser (Block Engineering) as the illumination source and a TE cooled mercury cadmium telluride (MCT) detector (Boston Electronics). All images were acquired using a 0.74NA objective. Infrared absorption images at discrete wavenumbers of interest were acquired with a pixel size of 2 microns. All measurements were made in transflection mode on infrared reflective low-emissivity slides (Kevley Technologies). The discrete frequency images were aligned using the image processing toolbox in MATLAB prior to ratioing to minimize any scanning artifacts. Adjacent tissue sections were stained with the anti-amyloid MOAB-2 antibody (Sigma Aldrich) at the University of Alabama Birmingham pathology core research lab. Brightfield optical images of stained tissues were acquired at 40x magnification using an Olympus BX43 microscope.

Spectral analysis

Spectra were smoothed using (3, 7) Savitzky-Golay filter and a linear baseline correction was performed. All spectral analysis was carried using the MATLAB software package.

Spectral deconvolution using Non-Negative Matrix Factorization

NMF is a blind spectral deconvolution approach which factors the spectra into a weighted sum of components or sub-bands similar to singular value decomposition (SVD), which has been used successfully for deconvolution of infrared spectra3841. The key difference between NMF and SVD is that the latter allows for spectral components to have negative values, whereas NMF does not. Since infrared absorbances cannot be negative, NMF is a more suitable choice for infrared spectral deconvolution that produces physical intuitive results. In NMF, the non-negative spectra matrix S into decomposed into two lower -ranked non-negative matrices as: S = M·C. Here M is a matrix that contains the component spectra, while C contains the weights or populations of each component. The optimal matrices M and C are iteratively determined to minimize the residual between the original spectral data the product of the lower rank approximations. The NMF analysis was performed on the entire spectral set, which makes this approach similar to global fitting: essentially every spectrum is decomposed as a weighted sum of the same components. The number of components was determined to be 3 using the L-curve approach42, 43.

Results and Discussion

The aggregation of Aβ42 was carried out with 60 μM of Aβ42 in 1x phosphate buffer saline (PBS) at 37°C without any agitation. The aggregation was monitored by depositing the aggregation mixture at different time intervals and acquiring AFM images. For acquiring IR spectra, first a high-resolution AFM image of the sample was captured and then spectra were recorded at different regions of interest. The spatial locations corresponding to the spectra are shown in Figure S1. Oligomers, protofibrils and fibrils were observed at different stages of aggregation. Figure 2A shows the AFM topographic image of Aβ42 oligomers observed after 3 days. Single isolated individual oligomers can be visualized. In addition to oligomers, elongated protofibrillar aggregates are also observed alongside oligomers, which are discussed later. The observed oligomeric species are globular or spherical in morphology; the height of these globular aggregates was measured to be 2.6±0.6 nm (Figure S2). Representative IR spectra recorded from these oligomeric species are shown in Figure 2B; additional spectra are shown in the Supporting Information (Figure S3A). The amide I absorption band exhibits significant heterogeneities between different oligomers and a single spectral type cannot be attributed to the oligomeric aggregates. The amide I band shows distinct peaks at 1634 cm−1 and 1666 cm−1. It is well known that amide-I infrared spectra are reflective of protein secondary structure, and thus the observation of different spectral types for oligomers clearly demonstrates that despite no significant morphological differences, early-stage oligomeric aggregates have significant variations in secondary structure. Interpreting the structural implications of the peaks observed and understanding the relative distributions of secondary structures contributing to the spectra requires spectral deconvolution, which we discuss later. We also note that the amide II absorption band has also been shown to be effective at discerning secondary structures4446; however, the structural implications of the amide I vibration and association of specific amide I frequencies to particular secondary structures has been studied in significantly more detail44, 4749. Hence, we limit our spectral analysis to the amide I absorption only.

Figure 2. Structural characterization of individual early-stage Aβ42 aggregates.

Figure 2.

(A) AFM topographic image of Aβ42 oligomers generated after 3 days of incubation in PBS buffer. (B) Representative IR spectra of the amide I region obtained from different individual oligomers. (C) AFM image of Aβ42 protofibril and (D) corresponding IR spectra recorded from different regions of the protofibril cluster.

Protofibrillar aggregates were observed alongside oligomers. The morphology of a single protofibrillar aggregate is shown in Figure 2C. The protofibril appears significantly different from the usual amyloid fibril morphology. The protofibrils observed do not appear to be smooth, rod-like amyloid fibrils, rather they are composed of individual globular aggregates attached with each other along the long axis of the protofibrils (Figure 2C). This feature is more evident when the topographic image is shown in a rainbow color scheme (Figure S4A), and also in the cross-sectional profile along the long axis (Figure S4B), which exhibits multiple peaks, and strongly indicates the presence of individual oligomeric features in the composition of protofibrils. IR spectra were recorded at arbitrarily chosen points on different protofibrils, and also along the length of the protofibrillar aggregate shown in Figure 2C. Representative spectra are shown in Figure 2D. It is evident that the amide I absorption bands shows distinct differences between different protofibrils (Figure S3B) and also within a single protofibril. The spectral variations are consistent with those observed for oligomers: the spectra exhibit a peak around ~1632 cm−1 with a second shoulder peak at ~ 1666 cm−1. In some spectra, the intensities of these bands are nearly equal, leading to a plateau like appearance for the spectra from 1630–1670 cm−1. These spectral heterogeneities indicate the presence of varied secondary structures of Aβ42 in protofibrils. The spectral similarities between oligomeric species and protofibrils strongly suggest that the protofibril formation involves integration of individual oligomers which retain their structural facets even after incorporation into the protofibrillar structure.

To understand the effect of this heterogeneity on later stage aggregates, we investigated the structural distribution of fibrils. Amyloid fibrils were mostly observed after 7 days of incubation. Figure 3A shows the AFM topographic image of a representative fibril. The fibril morphology is distinctly different compared to the protofibrils and no distinct globular bead like features along the fibril axis are detected. The height of the fibril, as measured at different regions of the fibril, is plotted as a histogram in Figure S5. The mean height is 11.5±5.2 nm which is significantly higher compared to the protofibrils. Additional fibril images are also shown in Figure S5. Similar to the protofibrils, IR spectra were acquired at multiple points along the fibril axis and representative spectra are shown in Figure 3B. Additional spectra are shown in Figure S2. The spectra exhibit similar heterogeneity observed in earlier aggregates with peaks at ~ 1660 cm−1, ~ 1630 cm−1 or both. We note that some fibrillar spectra exhibit a distinct difference from those described above and show a broad amide I absorption centered at ~1668cm−1 or even a distinct peak at ~1680cm−1, which suggests the possibility of a different secondary structure in fibrils absent in earlier oligomers.

Figure 3. Structural characterization of Aβ42 fibrils and later-stage oligomers.

Figure 3.

(A) AFM image of the Aβ42 fibril on gold substrate. (B) IR spectra obtained from different points along the fibril long axis. (C) AFM image of the Aβ42 oligomers observed alongside fibrils. (B) Representative IR spectra recorded from different oligomers.

In addition to fibrils, we have also observed a significant number of oligomers after 7 days of aggregation, as shown in the AFM topographic image (Figure 3C). The height value of these oligomers has been measured to be 3.1 ±0.7 nm (Figure S6). IR spectra have been recorded on these individual oligomers and shown in Figure 3D and Figure S3. Interestingly, the amide I absorption band does not show heterogeneity, as opposed to the spectra observed for the oligomers generated before the fibril formation. The peak of the absorption band is centered around ~ 1668 cm−1, similar to some of the spectra observed in fibrils, indicating that these oligomers can be participating in fibril formation. Interestingly, these oligomers do not exhibit the peak around ~1630 cm−1, indicating a distinct deviation from 3-day oligomeric structure, which could potentially hinder their participation in further fibril formation, consistent with their abundance at later stages of aggregation.

These results unequivocally demonstrate that early-stage Aβ42 aggregates are polymorphic in their structure, and the structural diversity in oligomers is retained and propagated to protofibrils and fibrils. This is a particularly surprising observation, since it is expected that the aggregation mechanism involves a transition from more disordered oligomeric species to ordered fibrils15, 4952. Our observations indicate that fibrils may not be necessarily having the ordered structures they are envisioned to be, and the structural variations and/or disorder of early-stage aggregates can still persist in fibrils. It is known from solid state NMR and more recent cryo-EM studies that a part of the polypeptide sequence can exist in a disordered state even in highly ordered amyloid fibrils5355. In fact, spectral line broadening in infrared measurements of amyloid species have been observed and attributed to structural disorder49, 51, 55. However, in all cases, the structural disorder has been assumed to arise only from different degrees of ordering within the amyloid peptide, and not from coexisting physical domains exhibiting variations in secondary structure. To the best of our knowledge, heterogeneities in secondary structure of beta amyloid aggregates that are not reflected in morphology have not been identified before. Previous AFM-IR studies on α-synuclein aggregates have revealed variations in secondary structure between spherical and elongated, ‘fibril-like’ oligomers56. Our results demonstrate for the first time that structural variations can arise from different oligomeric aggregates which in turn lead to spatial variations of secondary structure along a single amyloid fibril. Interestingly, we have previously identified structural heterogeneities in tau fibrils, wherein fibrils exhibiting different spectra were identified, but no significant spectral variations were observed within the same fibril57. To test if the observed heterogeneity is unique to Aβ42 or is persistent in other isomers, we investigated the Aβ40 fibrils. The nanoscale IR spectra of Aβ40 fibrils also exhibit similar spectral variations as observed for Aβ42 (Figure S7). These results hence point towards a fundamental difference in the structure of early-stage aggregates of beta amyloid and tau. It must be noted that the fibrillar structures investigated in this report are not mature fibrils, and the observations reported herein pertain to early stage fibrillar aggregates. It is possible that mature fibrils may exhibit less pronounced structural variations. The fibrillation kinetics observed in our experiments is consistent with prior reports that use micromolar concentrations of Aβ and neutral pH5860. However, the aggregation of Aβ is sensitive to a number of conditions, including, but not limited to concentration, pH, ionic strength, temperature, counterions and more6163. Hence potential effect of aggregation conditions and/or time on the structural ensemble cannot be ruled out. AFM-IR has been used to investigate beta amyloid aggregates before58, 59, 64, 65, but spectral variations along fibrils or heterogeneities observed herein have not been reported. This can stem from the difference in aggregation conditions used for these studies. Waeytens et. al.64 have reported averaged AFM-IR spectra of oligomers and fibrils aggregated at micromolar concentrations but under highly acidic conditions (pH 2.0). It is well known that acidic pH accelerates aggregation kinetics, and therefore the fibrillar structures observed by Waeytens et. al. may represent more mature aggregates different from the early-stage fibrils we observe. Ruggeri et. al.65 have investigated spectra of oligomers and fibrils at neutral pH albeit using a different approach for isolating monomers (treatment with guanidinium hydrochloride compared to hexafluoroisopropanol), which can contribute to altered conformational distributions and structural heterogeneities in aggregates. Similarly, Feuillie et. al.58 have reported the average of AFM-IR spectra of fibrils and oligomers, but have not discussed any possible variation in the spectra. Interestingly, Herzberg et. al.59 have shown spectral heterogeneity in prefibrillar aggregates, consistent with our observations. Previous AFM-IR studies on α-synuclein oligomeric species have also identified variations in secondary structure between morphologically different oligomers56. Taken together, this suggests that the choice of aggregation conditions can play a key role in modulating the structural ensemble of aggregates, and hence observation structural heterogeneity in amyloid aggregates can depend on the precise method followed for preparation and incubation of monomeric peptide for aggregation conditions. In this report we have focused on identifying the presence of structural heterogeneities in amyloid aggregates at different stages of aggregation. Assessing the effect of different incubation conditions on the structural distributions of the aggregates is not the focus of this report, and we aim to address it in future work.

The spectra, as described above, clearly indicate the presence of structural variations in early-stage amyloid aggregates. However, amide I spectra are usually convolutions of overlapping bands from different conformations, and hence the structural underpinnings of the AFM-IR spectra cannot be readily determined without spectral deconvolution. To get insights into the relative populations of secondary structures contributing to the spectra, we adopt a spectral deconvolution approach that utilizes non-negative matrix factorization (NMF)3941. The spectra of all the aggregates were deconvoluted together with NMF, which essentially makes this approach similar to global spectral fitting and allows for interpretation of spectral differences in terms of relative population of the same underlying sub-states. The details of the NMF analysis are provided in the method section. We find that 3 components/sub-bands adequately describe the spectral variations which are shown in Figure 4A. Component 1 has a peak centered at 1632cm−1 and a weaker shoulder at 1660cm−1. These features are representative of typical ordered parallel beta sheet spectra, as recorded for amyloid aggregates with FTIR49, 51, 52. The second component is primarily comprised of a broad peak at 1658cm−1. It is known that disordered random coil structures absorb at ~1654cm−1, whereas beta turns can exhibit bands typically at 1660cm−1 and higher66. Component 2 very likely represents contributions from both random coils and turns; however further deconvolution of this band can be challenging without a priori structural information. However, it should also be noted in this context that presence of significant populations of either of these structures represents a deviation from the ordered fibril structure; hence component 2 can be thought of representative of fibrillar structural disorder. The 3rd component exhibits a prominent peak at 1682cm−1, which is typically attributed to antiparallel beta sheets20, 52, 56. A weaker peak is observed at 1610cm−1, which is too low to be attributable to typical beta sheet structure. However, we note that Lomont and coworkers67 have reported the presence highly ordered beta sheets in amyloid beta aggregates with an absorption band at ~1614cm−1; so the possibility of certain beta sheet conformations exhibiting absorptions at lower than expected wavenumbers cannot be ruled out. Taken together, the deconvolution results indicate that the structural heterogeneity observed in the fibrillar and prefibrillar aggregates is reflective of an interplay between parallel and antiparallel beta structures and beta turns/random coils. Spectra with a prominent peak at between 1630–1635cm−1 represent a structural distribution that contains more parallel beta sheet, while those containing a dominant peak between 1656–1660cm−1 represent conformations that lack significant beta structure. And lastly, spectra with a peak at 1668cm−1 or higher represent conformations with distinct antiparallel structure in addition to turns. In the conventional view of amyloid aggregation, oligomers are believed to contain antiparallel beta sheets, which evolve into fibrils with parallel beta sheet structure. Our results show that oligomers generated in early stages of aggregation have significant structural variation, and the antiparallel beta sheet structure in oligomers becomes dominant with time. Given that protofibrils and fibrils exhibit the same structural heterogeneity as the early oligomers, and the abundance of ‘homogeneous’ oligomers alongside fibrils when they are expected to be incorporated into fibrils, these oligomeric species likely represent aggregation states that are less likely to be incorporated into fibrils. In that event, the heterogeneity can be argued to be favorable for formation of mature, ordered fibrils. Ahmad et. al. have shown that the structural transition to fibrils proceeds through oligomeric species that lack distinct beta structure, which is consistent with our observations, and support the hypothesis that the mature oligomers represent a conformation hindered in their ability to participate in fibril formation21. Evolutions into configurations that allow for fibrillar incorporation would require structural rearrangement, which could be energetically unattainable, implying these oligomers are off-pathway species that never integrate into fibrils. Nirmalraj and coworkers60 have shown that late-stage oligomers can coexist with mature Aβ 42 fibril networks, which indicates that not all oligomeric species eventually undergo structural rearrangement. Solid state NMR studies by Tay and coworkers68 have identified off-pathway oligomers with structural arrangements similar to antiparallel beta sheets, which is also consistent with our observations. Dear et. al.69 have shown that the majority of oligomers formed do not proceed to the fibrillar stage; the aggregates we see can be representative of such ensembles. The observation of antiparallel beta sheet character in fibrils is somewhat unexpected and deviates from the commonly expected parallel beta sheet structure of mature fibrils. However, antiparallel beta sheet structure in fibrils has been reported for certain mutants of beta amyloid70 and also for ganglioside induced aggregation71. Our results show that early-stage fibrils of wild-type Aβ formed without the interference of any external agents can have some antiparallel character which possibly evolves into parallel structures upon maturation. It should be noted that a comprehensive assessment of the structural distributions in different aggregation states and their evolution into mature fibrils with parallel cross beta structure requires structural analysis of aggregates at many more time points, which we aim to address in future work.

Figure 4. NMF deconvolution of IR spectra of aggregates.

Figure 4.

(A) Spectral components derived from NMF factorization of spectra. (B) Average spectrum of fibril showed in Figure 2A, determined by taking of spectra acquired along the fibril axis.

Observation of the aforementioned spectral heterogeneities leads rise to an important question, namely: do these persist in AD plaques? The spectral variations within a single fibril indicate that the average spectrum of individual fibrillar aggregates, shown in Figure 4B, can be very different from the conventional infrared absorptions associated with parallel beta sheets owing to the inherent structural variations described earlier. AFM is not a technique well-suited for tissue imaging, and hence extension of AFM-IR towards characterizing plaques is experimentally challenging. Infrared confocal imaging, which integrates infrared spectroscopy with optical microscopy, is an approach ideal for tissue applications and allows for mapping the chemistry of amyloid aggregates in AD tissues while providing the same molecular contrast37, 72, 73. We have recently demonstrated the capabilities of infrared imaging towards identifying the chemical heterogeneities of plaques37, wherein we demonstrated that amyloid plaques of the same morphology can vary significantly in terms of their beta sheet content. The heterogeneity in the amyloid aggregates observed in this study are in excellent agreement with our prior work and provide a molecular-level explanation of the plaque chemical variations. To further validate and test the generality of our prior results, here we expand on this work and apply infrared imaging to map plaques in AD temporal lobe tissue. Amyloid plaques were identified in the tissue sections by immunohistochemical staining using a beta amyloid specific antibody (MOAB-2)37, 74. For IR imaging, we used an unstained section adjacent to the IHC stained section so that spectra could be acquired without the interference from stains. Amyloid plaques can be broadly categorized to cored and non-cored morphologies1, 5. Cored plaques have been shown to contain fibrillar aggregates their center; therefore, it is expected that that cored plaques will exhibit increased beta sheet content compared to adjacent tissue. Figure 5AD show optical images of four IHC stained cored plaques which are expected to contain fibrillar amyloid aggregates at their core. For visualization of the beta sheet content of the plaques, we plot the spatial map of the ratio of the spectral intensity at 1628cm−1 normalized to the intensity at 1660cm−1 in Figure 5EH, which has been demonstrated to be reflective of the beta sheet content in amide-I spectra37, 73. Representative spectra from the plaque core and from outside the plaque boundaries are shown in Figures 5IL. Additional spectra depicting the variation across the core of a plaque are shown in Figure S8. It can be clearly seen that the plaques shown in Figures 5AB, while expected to contain fibrils with parallel beta sheet structure, exhibit very little beta sheet signature as evidenced by lack of bright pixels within the plaque boundary. This is not representative of all amyloid plaques, however, and we observe cored plaques with the expected beta sheet signatures as shown in Figures 5CD and 5GH. A total of 19 cored plaques were identified through immunostaining in these tissues, and 8 contained beta sheets while 11 did not exhibit significant beta sheet signatures. The full tissue IHC and infrared ratio images are shown in Figure S9 and S10 respectively. The infrared absorbance images at 1628cm−1 and 1660cm−1 of the full tissue section and of the individual plaque areas in Figure 5AH are shown in Figure S11. The lack of enhanced beta sheet signatures from plaques can have two possible explanations: either the plaques do not contain any fibrils, or the fibrils have no significant beta sheet structure. Our AFM-IR results indicate that the spectra of fibrils can often deviate from those characteristic of beta sheets, and hence supports the possibility that cored plaques do have fibrils, which however, can lack beta structure. These observations are consistent with our prior reports and provide unequivocal evidence that the heterogeneities observed in individual amyloid aggregates can also manifest themselves in AD plaques and can thus also have potential clinical significance. The implications of these heterogeneities in AD progression and their prevalence in different stages of AD will be addressed in future work.

Figure 5. Infrared microscopy of amyloid plaques.

Figure 5.

(A, B, C, D) Optical images of immunohistochemically stained cored amyloid plaques. (E, F, G, H) Corresponding IR ratio images (1628cm-1:1660cm-1) depicting the abundance of beta sheets. The data were acquired from a diseased AD temporal lobe tissue section. (I, J, K, L) Representative spectra from the plaque core (red) and from outside the plaque boundary (black). The spatial locations corresponding to the spectra are marked in the IHC images with stars.

Conclusions

In this study, we have demonstrated for the very first time that early-stage amyloid aggregates are structurally heterogeneous, and these heterogeneities are transmitted from prefibrillar aggregates to fibrils. The heterogeneity is reflected in the infrared spectra and variations therein of individual aggregates. The structural variation along a single fibril species indicate that amyloid fibrils may not necessarily be perfectly ordered which is not apparent from spatially averaged measurements. Deconvolution of the spectra show that the distributions are rooted in the relative distribution of beta sheets and beta turns. These results point to a scenario where the average spectrum of fibrils can lack the typical beta sheet signatures, indicating that amyloid aggregates and beta sheets are not always synonymous as they are often interpreted to be. We have validated this observation through infrared microscopy of amyloid plaques in tissues and show that plaques that are expected to contain fibrils can often lack beta sheet structure.

In summary, the results reported herein underscore the need for spatially resolved spectroscopy of amyloid aggregates and strongly establish the capabilities of AFM-IR as a method of choice for identifying the structural variations within different subgroups of aggregates and their evolution. These results can pave the way towards subtyping of plaques using amyloid secondary structure and can potentially unlock novel therapeutic strategies for Alzheimer’s disease.

Supplementary Material

Supporting Information

ACKNOWLEDGMENT

This work was supported by the National Institutes of Health (Award 1 R35 GM138162 to A.G.). The authors thank Dr. Dezhi Wang at UAB Pathology Core Facility for help with IHC staining.

Footnotes

The authors declare no competing financial interests.

ASSOCIATED CONTENT

Supporting Information.

The following files are available free of charge.

Locations of AFM topographs from where the IR spectra are recorded, AFM image of Aβ42 oligomers and their height distribution, additional IR spectra for oligomers, protofibrils and fibrillar aggregates; AFM image and height distribution of Aβ42 protofibrils and fibrils; AFM image of Aβ42 oligomers present in the fibril sample; AFM image and IR spectra of Aβ40 fibrils; optical and infrared images of amyloid plaques exhibiting beta sheet signatures in tissues. (PDF)

REFERENCES

  • 1.Perl DP Neuropathology of alzheimer’s disease. Mt. Sinai. J. Med. 2010, 77, 32–42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Hardy J; Higgins G Alzheimer’s disease: The amyloid cascade hypothesis. Science 1992, 256, 184. [DOI] [PubMed] [Google Scholar]
  • 3.Selkoe DJ; Hardy J The amyloid hypothesis of alzheimer’s disease at 25 years. EMBO Mol. Med. 2016, 8, 595–608. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Melzer TR; Stark MR; Keenan RJ; Myall DJ; MacAskill MR; Pitcher TL; Livingston L; Grenfell S; Horne K-L; Young BN, et al. Beta amyloid deposition is not associated with cognitive impairment in parkinson’s disease. Front. Neurol. 2019, 10, 391–391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Serrano-Pozo A; Frosch MP; Masliah E; Hyman BT Neuropathological alterations in alzheimer disease. Cold Spring Harb Perspect. Med 2011, 1, a006189–a006189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Baglioni S; Casamenti F; Bucciantini M; Luheshi LM; Taddei N; Chiti F; Dobson CM; Stefani M Prefibrillar amyloid aggregates could be generic toxins in higher organisms. J. Neurosci. 2006, 26, 8160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Bucciantini M; Calloni G; Chiti F; Formigli L; Nosi D; Dobson CM; Stefani M Prefibrillar amyloid protein aggregates share common features of cytotoxicity. J. Biol. Chem. 2004, 30, 31374. [DOI] [PubMed] [Google Scholar]
  • 8.Lambert MP; Barlow AK; Chromy BA; Edwards C; Freed R; Loisatos M; Morgan TE; Rozovsky I; Tromber B; Viola KL, et al. Diffusible, nonfibrillar ligands derived from abeta1–42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 6448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Lesné SE; Sherman MA; Grant M; Kuskowski M; Schneider JA; Bennett DA; Ashe KH Brain amyloid-β oligomers in ageing and alzheimer’s disease. Brain 2013, 136, 1383–1398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Wickramasinghe A; Xiao Y; Kobayashi N; Wang S; Scherpelz KP; Yamazaki T; Meredith SC; Ishii Y Sensitivity-enhanced solid-state nmr detection of structural differences and unique polymorphs in pico- to nanomolar amounts of brain-derived and synthetic 42-residue amyloid-β fibrils. J. Am. Chem. Soc. 2021, 143, 11462–11472. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Elkins MR; Wang T; Nick M; Jo H; Lemmin T; Prusiner SB; DeGrado WF; Stöhr J; Hong M Structural polymorphism of alzheimer’s β-amyloid fibrils as controlled by an e22 switch: A solid-state nmr study. J. Am. Chem. Soc. 2016, 138, 9840–9852. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Colvin MT; Silvers R; Ni QZ; Can TV; Sergeyev I; Rosay M; Donovan KJ; Michael B; Wall J; Linse S, et al. Atomic resolution structure of monomorphic aβ42 amyloid fibrils. J. Am. Chem. Soc. 2016, 138, 9663–9674. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Theint T; Xia Y; Nadaud PS; Mukhopadhyay D; Schwieters CD; Surewicz K; Surewicz WK; Jaroniec CP Structural studies of amyloid fibrils by paramagnetic solid-state nuclear magnetic resonance spectroscopy. J. Am. Chem. Soc. 2018, 140, 13161–13166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Truex NL; Wang Y; Nowick JS Assembly of peptides derived from β-sheet regions of β-amyloid. J. Am. Chem. Soc. 2016, 138, 13882–13890. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Antzutkin ON; Balbach JJ; Leapman RD; Rizzo NW; Reed J; Tycko R Multiple quantum solid-state nmr indicates a parallel, not antiparallel, organization of beta-sheets in alzheimer’s beta-amyloid fibrils. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 13045–13050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Murphy MP; LeVine H 3rd. Alzheimer’s disease and the amyloid-beta peptide. J Alzheimer’s Dis 2010, 19, 311–323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Lu J-X; Qiang W; Yau W-M; Schwieters CD; Meredith SC; Tycko R Molecular structure of β-amyloid fibrils in alzheimer’s disease brain tissue. Cell 2013, 154, 1257–1268. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Tycko R Amyloid polymorphism: Structural basis and neurobiological relevance. Neuron 2015, 86, 632–645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Chimon S; Shaibat MA; Jones CR; Calero DC; Aizezi B; Ishii Y Evidence of fibril-like β-sheet structures in a neurotoxic amyloid intermediate of alzheimer’s β-amyloid. Nat. Struct. Mol. Biol. 2007, 14, 1157. [DOI] [PubMed] [Google Scholar]
  • 20.Cerf E; Sarroukh R; Tamamizu-Kato S; Breydo L; Derclaye S; Dufrêne Yves F.; Narayanaswami V; Goormaghtigh E; Ruysschaert J-M; Raussens V Antiparallel β-sheet: A signature structure of the oligomeric amyloid β-peptide. Biochem. J. 2009, 421, 415–423. [DOI] [PubMed] [Google Scholar]
  • 21.Ahmed M; Davis J; Aucoin D; Sato T; Ahuja S; Aimoto S; Elliott JI; Van Nostrand WE; Smith SO Structural conversion of neurotoxic amyloid-beta(1–42) oligomers to fibrils. Nat. Struct. Mol. Biol. 2010, 17, 561–567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Fändrich M; Nyström S; Nilsson KPR; Böckmann A; LeVine H 3rd; Hammarström P Amyloid fibril polymorphism: A challenge for molecular imaging and therapy. J. Intern. Med. 2018, 283, 218–237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Close W; Neumann M; Schmidt A; Hora M; Annamalai K; Schmidt M; Reif B; Schmidt V; Grigorieff N; Fändrich M Physical basis of amyloid fibril polymorphism. Nat. Commun. 2018, 9, 699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Qiang W; Yau W-M; Lu J-X; Collinge J; Tycko R Structural variation in amyloid-β fibrils from alzheimer’s disease clinical subtypes. Nature 2017, 541, 217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Kollmer M; Close W; Funk L; Rasmussen J; Bsoul A; Schierhorn A; Schmidt M; Sigurdson CJ; Jucker M; Fändrich M Cryo-em structure and polymorphism of aβ amyloid fibrils purified from alzheimer’s brain tissue. Nat. Commun. 2019, 10, 4760. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Gremer L; Schölzel D; Schenk C; Reinartz E; Labahn J; Ravelli RBG; Tusche M; Lopez-Iglesias C; Hoyer W; Heise H, et al. Fibril structure of amyloid-β(1–42) by cryo-electron microscopy. Science 2017, 358, 116–119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Yang Y; Arseni D; Zhang W; Huang M; Lövestam S; Schweighauser M; Kotecha A; Murzin AG; Peak-Chew SY; Macdonald J, et al. Cryo-em structures of amyloid-aβ42 filaments from human brains. Science 2022, 375, 167–172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Ghosh U; Thurber KR; Yau W-M; Tycko R Molecular structure of a prevalent amyloid-β fibril polymorph from alzheimer’s disease brain tissue. Proc. Natl. Acad. Sci. U.S.A. 2021, 118, e2023089118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Dazzi A; Prater CB Afm-ir: Technology and applications in nanoscale infrared spectroscopy and chemical imaging. Chem. Rev. 2017, 117, 5146–5173. [DOI] [PubMed] [Google Scholar]
  • 30.Dazzi A; Prater CB; Hu Q; Chase DB; Rabolt JF; Marcott C Afm-ir: Combining atomic force microscopy and infrared spectroscopy for nanoscale chemical characterization. Appl. Spectrosc. 2012, 66, 1365. [DOI] [PubMed] [Google Scholar]
  • 31.Centrone A Infrared imaging and spectroscopy beyond the diffraction limit. Annu. Rev. Anal. Chem. 2015, 8, 101–126. [DOI] [PubMed] [Google Scholar]
  • 32.Katzenmeyer AM; Holland G; Chae J; Band A; Kjoller K; Centrone A Mid-infrared spectroscopy beyond the diffraction limit via direct measurement of the photothermal effect. Nanoscale 2015, 7, 17637–17641. [DOI] [PubMed] [Google Scholar]
  • 33.Ruggeri FS; Mannini B; Schmid R; Vendruscolo M; Knowles TPJ Single molecule secondary structure determination of proteins through infrared absorption nanospectroscopy. Nat. Commun. 2020, 11, 2945. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Kenkel S; Mittal S; Bhargava R Closed-loop atomic force microscopy-infrared spectroscopic imaging for nanoscale molecular characterization. Nat. Commun. 2020, 11, 3225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Jan A; Hartley DM; Lashuel HA Preparation and characterization of toxic aβ aggregates for structural and functional studies in alzheimer’s disease research. Nat. Protoc. 2010, 5, 1186–1209. [DOI] [PubMed] [Google Scholar]
  • 36.Mittal S; Yeh K; Leslie LS; Kenkel S; Kajdacsy-Balla A; Bhargava R Simultaneous cancer and tumor microenvironment subtyping using confocal infrared microscopy for all-digital molecular histopathology. Proc. Natl. Acad. Sci. U.S.A. 2018, 115, E5651. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Confer MP; Holcombe BM; Foes AG; Holmquist JM; Walker SC; Deb S; Ghosh A Label-free infrared spectroscopic imaging reveals heterogeneity of β-sheet aggregates in alzheimer’s disease. J. Phys. Chem. Lett 2021, 12, 9662–9671. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Kirschbaum C; Greis K; Mucha E; Kain L; Deng S; Zappe A; Gewinner S; Schöllkopf W; von Helden G; Meijer G, et al. Unravelling the structural complexity of glycolipids with cryogenic infrared spectroscopy. Nat. Commun. 2021, 12, 1201–1201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Thomas DA; Chang R; Mucha E; Lettow M; Greis K; Gewinner S; Schöllkopf W; Meijer G; von Helden G Probing the conformational landscape and thermochemistry of DNA dinucleotide anions via helium nanodroplet infrared action spectroscopy. Phys. Chem. Chem. Phys. 2020, 22, 18400–18413. [DOI] [PubMed] [Google Scholar]
  • 40.Ghosh A; Mukherjee P; Deb S; Bhargava R Mapping solvation environments in porous metal–organic frameworks with infrared chemical imaging. J. Phys. Chem. Lett 2017, 8, 5325–5330. [DOI] [PubMed] [Google Scholar]
  • 41.Pauca VP; Piper J; Plemmons RJ Nonnegative matrix factorization for spectral data analysis. Linear Algebra Appl. 2006, 416, 29–47. [Google Scholar]
  • 42.Hansen PC; O’Leary DP The use of the l-curve in the regularization of discrete ill-posed problems. SIAM J. Sci. Comput. 1993, 14, 1487–1503. [Google Scholar]
  • 43.Vangara R; Bhattarai M; Skau E; Chennupati G; Djidjev H; Tierney T; Smith JP; Stanev VG; Alexandrov BS Finding the number of latent topics with semantic non-negative matrix factorization. IEEE Access 2021, 9, 117217–117231. [Google Scholar]
  • 44.Barth A Infrared spectroscopy of proteins. Biochim. Biophys. Acta, Bioenerg 2007, 1767, 1073–1101. [DOI] [PubMed] [Google Scholar]
  • 45.Dousseau F; Pezolet M Determination of the secondary structure content of proteins in aqueous solutions from their amide i and amide ii infrared bands. Comparison between classical and partial least-squares methods. Biochemistry 1990, 29, 8771–8779. [DOI] [PubMed] [Google Scholar]
  • 46.Murphy BM; D’Antonio J; Manning MC; Al-Azzam W Use of the amide ii infrared band of proteins for secondary structure determination and comparability of higher order structure. Curr. Pharm. Biotechnol. 2014, 15, 880–9. [DOI] [PubMed] [Google Scholar]
  • 47.Barth A; Zscherp C What vibrations tell us about proteins. Q. Rev. Biophys. 2002, 35, 369–430. [DOI] [PubMed] [Google Scholar]
  • 48.Baldassarre M; Li C; Eremina N; Goormaghtigh E; Barth A Simultaneous fitting of absorption spectra and their second derivatives for an improved analysis of protein infrared spectra. Molecules 2015, 20, 12599–622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Martial B; Lefèvre T; Auger M Understanding amyloid fibril formation using protein fragments: Structural investigations via vibrational spectroscopy and solid-state nmr. Biophys. Rev. 2018, 10, 1133–1149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Tycko R Solid-state nmr studies of amyloid fibril structure. Annu. Rev. Phys. Chem. 2011, 62, 279–299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Moran SD; Zanni MT How to get insight into amyloid structure and formation from infrared spectroscopy. J. Phys. Chem. Lett 2014, 5, 1984–1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Sarroukh R; Goormaghtigh E; Ruysschaert J-M; Raussens V Atr-ftir: A “rejuvenated” tool to investigate amyloid proteins. Biochim. Biophys. Acta., Biomembr. 2013, 1828, 2328–2338. [DOI] [PubMed] [Google Scholar]
  • 53.Au DF; Ostrovsky D; Fu R; Vugmeyster L Solid-state nmr reveals a comprehensive view of the dynamics of the flexible, disordered n-terminal domain of amyloid-β fibrils. J. Biol. Chem. 2019, 294, 5840–5853. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Wälti MA; Ravotti F; Arai H; Glabe CG; Wall JS; Böckmann A; Güntert P; Meier BH; Riek R Atomic-resolution structure of a disease-relevant aβ(1–42) amyloid fibril. Proc. Natl. Acad. Sci. U.S.A. 2016, 113, E4976–E4984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Ghosh U; Yau W-M; Tycko R Coexisting order and disorder within a common 40-residue amyloid-β fibril structure in alzheimer’s disease brain tissue. Chem. Commun. 2018, 54, 5070–5073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Zhou L; Kurouski D Structural characterization of individual α-synuclein oligomers formed at different stages of protein aggregation by atomic force microscopy-infrared spectroscopy. Anal. Chem. 2020, 92, 6806–6810. [DOI] [PubMed] [Google Scholar]
  • 57.Banerjee S; Ghosh A Structurally distinct polymorphs of tau aggregates revealed by nanoscale infrared spectroscopy. J. Phys. Chem. Lett 2021, 12, 11035–11041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Feuillie C; Lambert E; Ewald M; Azouz M; Henry S; Marsaudon S; Cullin C; Lecomte S; Molinari M High speed afm and nanoinfrared spectroscopy investigation of aβ1–42 peptide variants and their interaction with popc/sm/chol/gm1 model membranes. Front. Mol. Biosci 2020, 7:571696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Herzberg M; Szunyogh D; Thulstrup PW; Hassenkam T; Hemmingsen L Probing the secondary structure of individual aβ40 amorphous aggregates and fibrils by afm-ir spectroscopy. Chem. Bio. Chem 2020, 21, 3521–3524. [DOI] [PubMed] [Google Scholar]
  • 60.Nirmalraj Peter N; List J; Battacharya S; Howe G; Xu L; Thompson D; Mayer M Complete aggregation pathway of amyloid β (1–40) and (1–42) resolved on an atomically clean interface. Sci. Adv. 6, eaaz6014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Owen MC; Gnutt D; Gao M; Wärmländer SKTS; Jarvet J; Gräslund A; Winter R; Ebbinghaus S; Strodel B Effects of in vivo conditions on amyloid aggregation. Chem. Soc. Rev. 2019, 48, 3946–3996. [DOI] [PubMed] [Google Scholar]
  • 62.Faller P; Hureau C Reproducibility problems of amyloid-β self-assembly and how to deal with them. Front. Chem 2021, 8: 611227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Stine WB; Jungbauer L; Yu C; LaDu MJ, Preparing synthetic aβ in different aggregation states. In Alzheimer’s disease and frontotemporal dementia: Methods and protocols, Roberson ED, Ed. Humana Press: Totowa, NJ, 2011; pp 13–32. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Waeytens J; Van Hemelryck V; Deniset-Besseau A; Ruysschaert J-M; Dazzi A; Raussens V Characterization by nano-infrared spectroscopy of individual aggregated species of amyloid proteins. Molecules 2020, 25, 2899. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Ruggeri FS; Habchi J; Chia S; Horne RI; Vendruscolo M; Knowles TPJ Infrared nanospectroscopy reveals the molecular interaction fingerprint of an aggregation inhibitor with single aβ42 oligomers. Nat. Commun. 2021, 12, 688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Barth A; Zscherp C What vibrations tell about proteins. Q.Rev. Biophys. 2002, 35, 369–430. [DOI] [PubMed] [Google Scholar]
  • 67.Lomont JP; Rich KL; Maj M; Ho J-J; Ostrander JS; Zanni MT Spectroscopic signature for stable β-amyloid fibrils versus β-sheet-rich oligomers. J. Phys. Chem. B 2018, 122, 144–153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Tay WM; Huang D; Rosenberry TL; Paravastu AK The alzheimer’s amyloid-β(1–42) peptide forms off-pathway oligomers and fibrils that are distinguished structurally by intermolecular organization. J. Mol. Biol. 2013, 425, 2494–2508. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Dear AJ; Meisl G; Šarić A; Michaels TCT; Kjaergaard M; Linse S; Knowles TPJ Identification of on- and off-pathway oligomers in amyloid fibril formation. Chem. Sci. 2020, 11, 6236–6247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Qiang W; Yau W-M; Luo Y; Mattson MP; Tycko R Antiparallel β-sheet architecture in iowa-mutant β-amyloid fibrils. Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 4443–4448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Okada Y; Okubo K; Ikeda K; Yano Y; Hoshino M; Hayashi Y; Kiso Y; Itoh-Watanabe H; Naito A; Matsuzaki K Toxic amyloid tape: A novel mixed antiparallel/parallel β-sheet structure formed by amyloid β-protein on gm1 clusters. ACS Chem. Neurosci. 2019, 10, 563–572. [DOI] [PubMed] [Google Scholar]
  • 72.Rak M; Del Bigio MR; Mai S; Westaway D; Gough K Dense-core and diffuse aβ plaques in tgcrnd8 mice studied with synchrotron ftir microspectroscopy. Biopolymers 2007, 87, 207–217. [DOI] [PubMed] [Google Scholar]
  • 73.Röhr D; Boon BDC; Schuler M; Kremer K; Hoozemans JJM; Bouwman FH; El-Mashtoly SF; Nabers A; Großerueschkamp F; Rozemuller AJM, et al. Label-free vibrational imaging of different aβ plaque types in alzheimer’s disease reveals sequential events in plaque development. Acta Neuropathol. Commun. 2020, 8, 222. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Youmans KL; Tai LM; Kanekiyo T; Stine WB Jr; Michon S-C; Nwabuisi-Heath E; Manelli AM; Fu Y; Riordan S; Eimer WA, et al. Intraneuronal aβ detection in 5xfad mice by a new aβ-specific antibody. Mol. Neurodegener 2012, 7, 8. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supporting Information

RESOURCES